

Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212

Fax: (61-2) 9247 3932

E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

23 December 2004

The Manager - Companies Australian Stock Exchange Limited 20 Bridge Street SYDNEY NSW 2000

(9 pages by email)

Dear Madam,

SUCCESSFUL COMPLETION OF SHARE PURCHASE PLAN

Further to the Company's announcement dated 24 November 2004, the Directors are pleased to advise that the Biotron Share Purchase Plan ('SPP') has been well supported by the Company's shareholders.

In excess of 300 shareholders elected to participate in the SPP resulting in the allotment of 5,744,800 new fully paid ordinary shares for \$1,206,408.

In accordance with Listing Rule 3.10, I attach an Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities.

For further information, please contact Dr. Michelle Miller, CEO, on (61-2) 61258001 or Peter Nightingale, Company Secretary, on (61-2) 92478212.

Yours sincerely

Peter J. Nightingale Company Secretary

pjn2874

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity	
	BIOTRON LIMITED
ABN	
60 086 399 144	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares

Number of *securities issued or to be issued (if known) or maximum number which may be issued

5,744,800

Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares ranking pari passu with existing ordinary shares

⁺ See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

Yes

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

\$0.21 each

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

For the purposes as set out in the Biotron Share Purchase Plan dated 22 November 2004.

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

23 December 2004

Number and +class of all +securities quoted on ASX (*including* the securities in clause 2 if applicable)

Number	+Class
69,800,550	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

9	Number	and	+class	of	f all
	+securities	not	quoted	on	ASX
	(including	the	securities	in	clause
	2 if applica	ible)			

Number	+Class	
900,000	30/9/05 \$0.50 options	
250,000	14/1/07 \$0.60 options	
500,000	14/1/07 \$0.75 options	
500,000	14/1/07 \$1.00 options	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Remains unchanged

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
	ourousumg ourousums.	
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the	N/A
	entity has *security holders who will not be sent new issue documents	
	documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do ⁺ security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	How do *security holde of their entitlements (excepthrough a broker)?			
33	⁺ Despatch date	N/A		
	3 - Quotation of d only complete this section if	Securities ou are applying for quotation of securities		
34	Type of securities (tick one)			
(a)	√ Securities describe	in Part 1		
(b)	Example: restricted secur	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entit	ies that have ticke	d box 34(a)		
Addi	tional securities fo	rming a new class of securities		
Tick to	indicate you are providing nts	ne information or		
35	1 1	re ⁺ equity securities, the names of the 20 largest holders of the es, and the number and percentage of additional ⁺ securities held by		
36	1 1	are ⁺ equity securities, a distribution schedule of the additional at the number of holders in the categories		
37	A copy of any trus	deed for the additional +securities		

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which ⁺ quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		L	
		Number	+Class
10			Class
42	Number and *class of all *securities quoted on ASX (<i>including</i> the securities in clause 38)	N/A	

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

⁺ See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 23 December 2004

(Director/Company Secretary)

Print name: Peter J. Nightingale

__ __ __ __

⁺ See chapter 19 for defined terms.